OH Pharma
Products › Metabolism › Retatrutide 10 mg
Retatrutide 10 mg OH PharmaRetatrutide 10 mg OH Pharma – back of vial
Retatrutide 20 mg OH PharmaRetatrutide 20 mg OH Pharma – back of vial
Retatrutide 30 mg OH PharmaRetatrutide 30 mg OH Pharma – back of vial

Swipe to see the other strengths

Metabolism · File 01

Retatrutide 10 mg

Certificate of analysis available

✓Sterility and endotoxins tested by Nelson Labs (Salt Lake City)

Purity (HPLC)99.6 %
LotGN2605
LaboratoryBTLabs
Calculate a dose →

Description

Triple agonist peptide of the GIP, GLP-1 and glucagon receptors, three hormones involved in regulating appetite, blood sugar and energy expenditure.

Studied benefits

  • Substantial weight loss in trials.
  • Lower HbA1c in people with type 2 diabetes.
  • Improvement in knee osteoarthritis pain in some populations with obesity.
  • Improvement in obstructive sleep apnea in the relevant trials.

Results reported in published research; they guarantee no effect and are not an indication for use.

🔬 What the research says
  • Phase 2 trial (NEJM, 2023; 338 adults, 48 weeks): mean weight loss of up to 24.2% at the highest dose, versus about 2% on placebo.
  • Phase 3 trials TRIUMPH‑2 and TRIUMPH‑3 (80 weeks): weight reduction of up to 20.8% and 22.6% depending on the population studied.
⚠️ Warnings and reported side effects
  • Common digestive effects: diarrhea (24–34%), nausea (21–28%), constipation (16–18%), vomiting.
  • Dose-dependent increase in heart rate (phase 2).
  • Up to 13.5% of participants stopped treatment because of adverse effects, versus about 5% on placebo.
  • GLP‑1 agonist class warnings: pancreatitis, gallbladder disorders, thyroid tumours seen in rodents. Not recommended during pregnancy.

Consult a healthcare professional before any use. If an adverse effect occurs, stop use and see a doctor.

Certificate details

Laboratory
BTLabs (West Palm Beach, FL, United States)
Report number
IF-824-QSA-TR006-BTL26632-04
Substance analyzed
Retatrutide
Lot
GN2605
Analysis date
June 1, 2026
Report date
June 5, 2026
Labelled sample content
10 mg
Sample ID
005000040271684

Results

TestMethodSpecificationResult
Identity and composition (FTIR)USP <197A>Confirms the presence of the peptideConfirmedPass
Purity (HPLC)USP <621>≥ 98 %99.6 %Pass
Measured content (HPLC)USP <621>90 – 110 % de 10 mg12.4 mg (124 %)Out of specification
Total massUSP <41>As measured104.9 mg

According to the laboratory, this analysis covers identity, purity, content and composition. It does not cover particulates, microbial contamination or endotoxins. Sterility and endotoxins are tested separately by Nelson Labs (Salt Lake City, Utah).

How to read this certificate →

Original certificate

Certificate of analysis Retatrutide 10 mg, page 1Certificate of analysis Retatrutide 10 mg, page 2 Download the certificate (PDF)

Sources

  1. Jastreboff et al., NEJM 2023 — phase 2 trial
  2. Patient Care — TRIUMPH‑2 and ‑3 results (July 2026)
  3. Health Canada — advisory on unauthorized injectable peptides (April 2026)

For educational purposes only. This information summarizes published studies and is neither a recommendation for use nor medical advice.

← Back to products